Oryzon Genomics SA (ORN) Stock Statistics & Valuation Metrics

Oryzon Genomics SA has a market cap or net worth of €216.26M. The enterprise value is €146.68M.

Oryzon Genomics SA has 78,547,620 shares outstanding. The number of shares has decreased by -2.65% in one year.

Oryzon Genomics SA’s return on equity (ROE) is -0.04 and return on invested capital (ROIC) is -5.61%.

The current PE Ratio of Oryzon Genomics SA is -24.59. Oryzon Genomics SA’s PEG ratio is 0.00.

In the last 12 months, Oryzon Genomics SA had revenue of 7.36M and earned -3.67M in profits. Earnings per share was -0.06.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

Oryzon Genomics SA pays an annual dividend of ―, resulting in a dividend yield of ―

Oryzon Genomics SA upcoming earnings date is Jul 23, 2025, TBA Not Confirmed.

Oryzon Genomics SA as a current ratio of 0.75, with Debt / Equity ratio of 0.00%

In the past 12 months, Oryzon Genomics SA has paid 1.91M in taxes.

Oryzon Genomics SA EV to EBITDA ratio is -22.72, with an EV/FCF ratio of -17.70.

Oryzon Genomics SA has €5.62M in cash and marketable securities with €16.21M in debt, giving a net cash position of €10.59M billion.

Gross margin is 0.00%, with operating margin of -60.10%, and net profit margin of -49.81%.

The average price target for Oryzon Genomics SA is €8.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy